Skye Bioscience, Inc.
No enriched coverage for $SKYE in the last 7 days.
Schwab Andrew J. sold 148,079 indirectly-held shares of Skye Bioscience, Inc. (SKYE) at an average of $1.62 ($1.61–$1.65, $0.24M total) across 4 trades over 2026-09-22 to 2026-09-23.
5AM Partners VII, LLC sold 148,079 indirectly-held shares of Skye Bioscience, Inc. (SKYE) at an average of $1.62 ($1.61–$1.65, $0.24M total) across 4 trades over 2026-09-22 to 2026-09-23. Filed jointly with 5AM Ventures VII, L.P. (10% owner), 5AM Partners II, LLC (10% owner), 5AM Ventures II LP (10% owner), 5AM CO-INVESTORS II LP (10% owner), DIEKMAN JOHN D (10% owner), PARMAR KUSH (10% owner) and ROCKLAGE SCOTT M (10% owner).
Skye Bioscience, Inc. (SKYE) filed an SEC Form 8-K — Termination of a Material Definitive Agreement. Item 1.02 Termination of a Material Definitive Agreement. On September 8, 2026, in connection with the resignation of John P. Sharp as Chief Financial Officer and principal financial and accounting officer of Skye Bioscience, Inc., a Nevada corporation (the “Company”), the Compan
Recent SKYE coverage spans insider activity, corporate actions and mergers & acquisitions.
In the last 30 days, SKYE insiders filed 12 SEC Form 4 transactions — no purchases and 12 sales ($609K). The most active reporter was 5AM Partners VII, LLC with 6 filings.
Insider sale may signal lack of confidence, modest negative pressure on stock.
The insider sale removes a 10% owner, potentially signaling lack of confidence and could pressure the stock lower.
Leadership change and contract termination may cause short‑term volatility and affect operational continuity.
Potential dilution and cash infusion could modestly support the stock price, but the limited size limits impact.
Acquisition adds a Crohn's disease program and financing of $125 million.
AlphAI scores every news story that mentions SKYE with an AI model for sentiment and relevance, and aggregates insider trades from Skye Bioscience, Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
Schwab Andrew J. sold 148,079 indirectly-held shares of Skye Bioscience, Inc. (SKYE) at an average of $1.62 ($1.61–$1.65, $0.24M total) across 4 trades over 2026-09-22 to 2026-09-23.
1 min read5AM Partners VII, LLC sold 148,079 indirectly-held shares of Skye Bioscience, Inc. (SKYE) at an average of $1.62 ($1.61–$1.65, $0.24M total) across 4 trades over 2026-09-22 to 2026-09-23. Filed jointly with 5AM Ventures VII, L.P. (10% owner), 5AM Partners II, LLC (10% owner), 5AM Ventures II LP (10% owner), 5AM CO-INVESTORS II LP (10% owner), DIEKMAN JOHN D (10% owner), PARMAR KUSH (10% owner) and ROCKLAGE SCOTT M (10% owner).
1 min readSkye Bioscience, Inc. (SKYE) filed an SEC Form 8-K — Termination of a Material Definitive Agreement. Item 1.02 Termination of a Material Definitive Agreement. On September 8, 2026, in connection with the resignation of John P. Sharp as Chief Financial Officer and principal financial and accounting officer of Skye Bioscience, Inc., a Nevada corporation (the “Company”), the Compan
2 min readSkye Bioscience, Inc. (SKYE) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. Item 1.01 Entry into a Material Definitive Agreement. As previously disclosed on the Current Report on Form 8-K filed by Skye Bioscience, Inc., a Nevada corporation (the “Company”), with the U.S. Securities and Exchange Commission (the “SEC”) on August 14, 2026, concurrently with
2 min readUltragenyx (RARE) and Regeneron (REGN) received FDA approvals for GENGLYCOS and Pasatru, respectively. BioMarin (BMRN) acquired Alesta for $490M. Humacyte (HUMA) and Eyepoint (EYPT) faced trial setbacks. Key financials: RARE -$25.32, REGN -$826.64, BMRN -$67.68, HUMA -$0.68.
3 min readSchwab Andrew J. sold 375,840 indirectly-held shares of Skye Bioscience, Inc. (SKYE) at an average of $0.37 ($0.32–$0.38, $0.14M total) across 9 trades over 2026-08-18 to 2026-08-20.
1 min read5AM Partners VII, LLC sold 375,840 indirectly-held shares of Skye Bioscience, Inc. (SKYE) at an average of $0.37 ($0.32–$0.38, $0.14M total) across 9 trades over 2026-08-18 to 2026-08-20. Filed jointly with 5AM Ventures VII, L.P. (10% owner), 5AM Partners II, LLC (10% owner), 5AM Ventures II LP (10% owner), 5AM CO-INVESTORS II LP (10% owner), DIEKMAN JOHN D (10% owner), PARMAR KUSH (10% owner) and ROCKLAGE SCOTT M (10% owner).
1 min readSkye Bioscience (SKYE) will acquire Redx Pharma via a scheme of arrangement, creating Nasdaq-listed Fibrx Therapeutics led by Redx management. The lead asset is RXC008 for fibrostenotic Crohn’s, with FDA Fast Track and Phase 2 topline data expected in H2 2028. Financing totals $125M, including a $68M PIPE and $36M Series A, funding operations into 2029. SKYE closed at $0.50.
4 min readSkye Bioscience (Nasdaq: SKYE) will acquire privately held Redx Pharma via a UK scheme of arrangement, forming Fibrx Therapeutics that will trade on Nasdaq. The deal includes about $125 million in committed financings, including a ~$68 million PIPE and a $36 million Series A. Funds are expected to support RXC008 Phase 2 through 2029, with topline data in H2 2028.
4 min readSkye Bioscience, Inc. (SKYE) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. Skye Bioscience and Redx Pharma Announce Transaction Agreement and $125 Million in Financings • Combined company to trade on Nasdaq and operate as Fibrx Therapeutics, a fibrosis-focused company led by the Redx management team and board • Company’s lead program will be RXC008, Red
4 min read